O
Ourania E. Tsitsilonis
Researcher at National and Kapodistrian University of Athens
Publications - 103
Citations - 2212
Ourania E. Tsitsilonis is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 22, co-authored 89 publications receiving 1712 citations.
Papers
More filters
Journal ArticleDOI
Harnessing the immune system to improve cancer therapy.
Nikos E. Papaioannou,Ourania V. Beniata,Panagiotis Vitsos,Ourania E. Tsitsilonis,Pinelopi Samara +4 more
TL;DR: The most popular cancer immunotherapy approaches are presented and their clinical relevance is discussed referring to data acquired from clinical trials.
Journal ArticleDOI
Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.
Constantin N. Baxevanis,Ioannis F. Voutsas,Ourania E. Tsitsilonis,Angelos D. Gritzapis,Roula Sotiriadou,Michael Papamichail +5 more
TL;DR: The data demonstrate for the first time in patients with metastatic cancer the essential role of CD4+ Th cell-activated DCs for optimal CD8+ T cell-mediated killing of autologous tumors and provide the basis for the design of novel protocols in cellular adoptive immunotherapy of cancer, utilizing synthetic peptides capable of inducing T cell help in vivo.
Journal ArticleDOI
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications.
Ioannis P. Trougakos,Kimon Stamatelopoulos,Evangelos Terpos,Ourania E. Tsitsilonis,Evmorfia Aivalioti,Dimitrios Paraskevis,Efstathios Kastritis,George N. Pavlakis,Meletios-Athanasios Dimopoulos +8 more
TL;DR: In this paper, the authors discuss SARS-CoV-2 life cycle and a number of approaches aiming to suppress viral infection rates or propagation; increase virus antigen presentation in order to activate a robust and durable adaptive immune response from the host, and/or mitigate the ARDS-related "cytokine storm" and collateral tissue damage that triggers the severe life-threatening complications of COVID-19.
Journal ArticleDOI
VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2.
Apostolos C. Ziogas,Nikos G. Gavalas,Marinos L. Tsiatas,Ourania E. Tsitsilonis,Ekaterini Politi,Evangelos Terpos,Alexandros Rodolakis,George Vlahos,Nikolaos Thomakos,Dimitrios Haidopoulos,Aristidis Antsaklis,Meletios A. Dimopoulos,Aristotle Bamias +12 more
TL;DR: Overall, this study shows that T cells secret VEGF and expresses VEGFR‐2 upon activation, and that V EGF significantly reduced the cytotoxic activity of T cells and that activated T cells secrete VEGf in the culture environment.
Journal ArticleDOI
VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
Nikos G. Gavalas,Marinos L. Tsiatas,Ourania E. Tsitsilonis,Ekaterini Politi,Kyriaki Ioannou,Argyrios Ziogas,Alexandros Rodolakis,G. Vlahos,N. Thomakos,Dimitrios Haidopoulos,E. Terpos,Aristidis Antsaklis,Meletios A. Dimopoulos,Aristotle Bamias +13 more
TL;DR: VEGF significantly reduced the number and proliferation rate of T cells in a dose-dependent manner and CD3+ T cells expressed VEGFR-2 on their surface upon activation and showed that ascites-derived T cells secrete VEGF and express VEG FR-2 upon activation.